This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Drummond, S. H Articles by Keefe, P. A Search for Related Content PubMed PubMed Citation Articles by Drummond, S. H Articles by Keefe, P. A Social Bookmarking                         What's this?

National survey of drug use in palliative care

Tasmanian School of Pharmacy, Faculty of Medicine and Pharmacy, University of Tasmania

Gregory M Peterson

Tasmanian School of Pharmacy, Faculty of Medicine and Pharmacy, University of Tasmania

James G Galloway

Director of Pharmacy, Repatriation General Hospital, Hobart

Patrick A Keefe

Launceston General Hospital, Launceston

The objective was to compile data on therapeutic approaches employed in palliative care in Australia, including practices relating to combining drugs in syringe drivers for administration by subcutaneous infusion. A questionnaire, with a reply-paid envelope, was sent to 130 teaching hospitals and palliative care services throughout Australia. Ninety-six responses were received (74% response rate). Drugs commonly administered in palliative care included oral morphine (97% of respondents), subcutaneous morphine (76%), oral metoclopramide (82%), subcutaneous metoclopramide (41%), oral dexamethasone (70%), oral haloperidol (50%), subcutaneous haloperidol (43%), oral prochlorperazine (47%), oral codeine (38%) and subcutaneous midazolam (36%). Drugs frequently combined in syringe drivers for subcutaneous infusion included morphine plus metoclopramide (67%), morphine plus midazolam (66%), and all three of these drugs (35%). Only 48% of the palliative care services had a policy on combining drugs in syringe drivers for administration by subcutaneous infusion and 34% had an upper limit on the number of drugs combined in syringe drivers. Twenty-nine per cent of respondents had encountered problems (e.g. incompatibilities) when combining drugs in syringe drivers for administration by subcutaneous infusion. This study has revealed considerable variation in the practice of therapeutics and the combining of drugs in syringe drivers for administration by subcutaneous infusion in palliative care.

Key Words: drug utilisation • prescriptions • drug • palliative treatment

Palliative Medicine, Vol. 10, No. 2, 119-124 (1996)
DOI: 10.1177/026921639601000206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Henderson, E MacGregor, N Sykes, and M Hotopf The use of benzodiazepines in palliative care Palliative Medicine, June 1, 2006; 20(4): 407 - 412. [Abstract] [PDF]

				C. Fonzo-Christe, C. Vukasovic, A.-F. Wasilewski-Rasca, and P. Bonnabry Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review Palliative Medicine, April 1, 2005; 19(3): 208 - 219. [Abstract] [PDF]

				G. Zeppetella How do terminally ill patients at home take their medication? Palliative Medicine, September 1, 1999; 13(6): 469 - 475. [Abstract] [PDF]